Parkinson’s disease monitoring app promising for advanced clinical decisions

[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2016/07/Kinesia1.png” thumb_width=”150″ /]A study in the July Journal of Parkinson’s Disease presents a small (N=40) study on the use of wearable sensor data and the KinesiaOne mobile app to assist in clinical decisions around advanced therapy referral for Parkinson’s disease patients. The KinesiaOne sensor is worn on the fingertip and tracks motor response on the mobile app (left). The patients were followed for one year, with half receiving standard care and half using motion sensor-based remote monitoring once per month in conjunction with standard care. Remote monitoring led to five times more advanced therapy patient referrals, compared to standard care alone (63.6 percent versus 11.8 percent, p <  0.01). These therapies are highly considered due to their nature–deep brain stimulation (DBS) or an implantable medication pump–and this initial screening may lead to more advanced algorithms and/or continuous monitoring, which the KinesiaOne developer, Great Lakes NeuroTechnologies, also has. Release, JPD abstract, Mobihealthnews Also see our short article on Ireland’s Beats Medical.

More on DARPA’s ‘brain chips’ for PTSD, TBI

DARPA’s continued research on deep brain stimulation (DBS) implants to treat PTSD and TBI, as well as other neuropsychological conditions, is given the once-over in this Defense One article. New information from the time this Editor last wrote about it in December is that the SUBNETS program (Systems-Based Neurotechnology for Emerging Therapies), funded with $12 to 26 million, will work with the University of California at San Francisco, Lawrence Livermore National Lab and Medtronic to create an implant with electrodes reaching into the brain and which does not require staying still under a machine in a lab. The prototype development is expected to take five years. The article also points out the US Air Force initiative studying the effects of low amounts of electricity on the brain to boost alertness delivered by an external cap.

Brain stimulation therapy explored by DARPA

[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2013/12/SUBNETS_144_144.png” thumb_width=”150″ /]The US Defense Advanced Research Projects Agency (DARPA) is investigating the use of DBS (deep brain stimulation) implants for possible treatment of several chronic neuropsychological conditions. They are seeking to evaluate neural and behavioral processes in PTSD, TBI, major depression, borderline personality disorder, general anxiety disorder, substance abuse/addiction and fibromyalgia/chronic pain through the SUBNETS program (Systems-Based Neurotechnology for Emerging Therapies). All these conditions are on the rise with service members and veterans. DBS is currently used in neurological diseases that impair motor function–Parkinson’s and dystonia–and is being researched for treatment of depression, obsessive compulsive disorder, Tourette’s and epilepsy. SUBNETS is also linked to NIH’s BRAIN Initiative. Armed With Science article, the SUBNETS pre-solicitation (Photo courtesy of DARPA)